Methods In order to examine the sensitivity of various tests and reagents for the detection of
the anticoagulant, three laboratories collected plasma samples from 24 patients previously …

Eighty-three patients with circulating anticoagulants were studied at The New York Hospital.
The lupus-type anticoagulant, an inhibitor of the prothrombin activator complex, was …

Patients with systemic lupus erythematosus (SLE) occasionally exhibit an acquired inhibitor
of coagulation. Of these, the most common is the 'lupus inhibitor'and this may be detected by …

An anticoagulant occurring in 4 of 6 patients with SLE has been demonstrated by a sensitive
assay utilizing an ammonium sulfate fraction of serum. The anticoagulant functions as an …

To define clinical and laboratory characteristics of the lupus anticoagulant (LA), we reviewed
our experience (219 subjects). Subjects were divided into group A, those with the LA and the …

The coagulation inhibitor known as the “lupus anticoagulant” was first clearly described in
systemic lupus erythematosus (SLE) by Conley and Hartmann in 1952. l Since then …

The clinical and laboratory experience with the lupus anticoagulant was reviewed in 37
patients. The anticoagulant is thought to act by blocking the activation of prothrombin by the …

1. A circulating anticoagulant in a suspected case of lupus erythematosus has been highly
purified by a combination of Sephadex gel filtration and DEAE cellulose chromatography. 2 …

Fourteen male patients examined for a prolonged partial thromboplastin time were found to
have the lupus anticoagulant. In contrast to previous reports, there was no increased …

Approximately 2% of the patients screened in our laboratories with activated partial
thromboplastin times are found to have a lupus anticoagulant. Recognition of lupus …